Additionally, treatment with IDO1 inhibitor has led to upregulated expression of enzymes within the KP [46], suggesting a multifaceted therapeutic potential in addressing the complex neuroinflammatory and metabolic disruptions characteristic of AD. The gene discussed is IDO1; the disease is Alzheimer disease.